<DOC>
	<DOCNO>NCT00496821</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability efficacy intranasal ALN-RSV01 versus placebo , administer daily 5 day healthy male volunteer experimentally inoculate RSV</brief_summary>
	<brief_title>Intranasal ALN-RSV01 Administered Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Availability require study period ( include inpatient phase , ability comply study requirement attend followup study visit Able provide write consent participation read Consent Form adequate opportunity discus study investigator qualify deputy . Good general health status determine screen evaluation great 120 day less 14 day prior enrollment admission research unit Low titer RSV neutralize antibody measure screening . Significant acute chronic , uncontrolled medical illness Presence household member close contact someone : Is less three ( 3 ) year age Has know immunodeficiency Is receive immunosuppressant drug Is undergo soon undergo cancer chemotherapy within 28 day enrollment Has diagnose emphysema , chronic obstructive pulmonary disease ( COPD ) , severe lung disease Is elderly reside nursing home , Has receive organ transplant Females eligible study Evidence history drug alcohol abuse ( within past 6 month ) positive urine drug alcohol screen Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Respiratory Syncytial Virus</keyword>
</DOC>